99. Precision medicine for sepsis, Tim Sweeney, Co-Founder and CEO, Inflammatix, Inc.

episode

Biotech 2050 Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Oura Delays IPO Over Market Uncertainty 2 min · 29 Sep 2026 · WSJ Minute Briefing

Win Brooke's Bucks (9/29/26) 11 min · 29 Sep 2026 · Brooke and Jeffrey

Ex-Disney CEO BREAKS SILENCE on Bob Iger & The Truth About Disney | PBD Podcast #864 1h 59m · 29 Sep 2026 · PBD Podcast

A Relaxing Visit to Ek Balam 44 min · 29 Sep 2026 · Get Sleepy: stories for sleep

Ep. 2070 - Republican Campaign Ad Brutalizes Lazy White Men 51 min · 29 Sep 2026 · The Michael Knowles Show

The Dollar-Store Hour: Why Doing It Yourself is Costing You Millions 3 min · 29 Sep 2026 · The Level Up Podcast w/ Paul Alex

Report any issue

Source

Recorded20 Apr 2022

Publisherfeeds.soundcloud.com ↗

Handlerec:2866869

Show notes

Tim Sweeney, MD, PhD, is co-founder and CEO of Inflammatix. Tim has extensive experience in medical practice (general & trauma surgery), bench research, and bioinformatics / machine learning. While training at Stanford he helped invent the core technology on which Inflammatix is based, is named on over a dozen patents related to medical diagnostics, and has published 100 manuscripts & abstracts. He is PI (through Inflammatix) on multiple development contracts from DARPA, BARDA, and NIH, and brought Inflammatix to recognition as the ‘Most Disruptive Technology’ at AACC in 2019, and the “Fierce 15” list in 2020.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in